Non-Invasive Monitoring Systems Stock

Non-Invasive Monitoring Systems Debt/EBITDA

The Total Debt to EBITDA Ratio of Non-Invasive Monitoring Systems (NIMU) as of Sep 5, 2026 is -3.72. In the previous year, Total Debt to EBITDA Ratio was -2.82 — a change of 31.64% (lower).

Debt/EBITDA

-3.72

YoY

31.64%

Last updated:

Total Debt to EBITDA Ratio of Non-Invasive Monitoring Systems is 2026 -3.72 . Total Debt to EBITDA Ratio of Non-Invasive Monitoring Systems was 2025 -2.82 . It decreases by 31.64% lower compared to the previous year.

The Non-Invasive Monitoring Systems Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2018
-11.94 USD
Jan 1, 2019
0.00 USD
Jan 1, 2020
0.00 USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
-0.94 USD
Jan 1, 2023
-1.78 USD
Jan 1, 2024
-2.82 USD
Jan 1, 2025
-3.72 USD
The Non-Invasive Monitoring Systems Debt/EBITDA history
YEARDebt/EBITDAYoY
-3.72+31.64%
-2.82+59.13%
-1.78+88.17%
-0.94
0.00
0.00
0.00-100.00%
-11.94+92.97%
-6.19+105.14%
-3.02-40.76%
-5.09+31.52%
-3.87
Access this data via the Eulerpool API

Non-Invasive Monitoring Systems Stock analysis

What does Non-Invasive Monitoring Systems do? Non-Invasive Monitoring Systems Inc (NIMS) has become a major player in the field of medical diagnostics and monitoring in recent years. The company was founded in 2002 and is headquartered in Miami, Florida. Its focus is on developing and marketing innovative non-invasive technologies that enable better patient care. NIMS' business model is based on the development and marketing of products that allow for fast and accurate diagnosis of various medical conditions. These technologies can be used in various clinical areas such as intensive care, oncology, cardiology, and neurology. The company's goal is to improve patient care by making diagnostics and monitoring faster, more accurate, and more effective. NIMS has several divisions that focus on different medical applications. One of these is the gastrointestinal division, which specializes in the diagnosis and monitoring of gastrointestinal disorders. NIMS offers innovative technologies such as magnetic resonance elastography (MRE-MRI), which allows for the measurement of tissue hardness without invasive procedures. This technology is particularly used in the early detection of cancer, as it enables the detection of tissue changes at an early stage. Another important division of NIMS is cardiovascular monitoring, which aims at the early detection and monitoring of heart diseases. The company offers various non-invasive technologies for this purpose, such as wearable devices for measuring blood pressure and heart rate, or ultrasound for measuring blood flow and vascular stiffness. These technologies are intended to improve the monitoring of patients with heart diseases and to detect complications at an early stage. NIMS also offers innovative diagnostic tools for the early detection of cancer, such as the Cancer Screening Index (CSI). The CSI is a biomarker-based test that calculates the probability of developing certain types of cancer. Various factors such as family history, smoking, or age are taken into account in the calculation. The CSI aims to contribute to the early detection of cancer and thus enable better prognosis. In addition to these products, NIMS is also involved in clinical research. The company offers specialized services such as conducting clinical trials or providing expert opinions. These services are intended to promote the development of new non-invasive diagnostic and monitoring technologies and thus improve overall patient care. Overall, NIMS has become a leading company in the field of non-invasive medical diagnostics and monitoring. The company is constantly striving to advance the development of new innovative technologies to improve patient care and minimize the use of invasive procedures. With its various divisions and products, NIMS is able to cover various medical applications and thus appeal to a broad customer base. Non-Invasive Monitoring Systems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Non-Invasive Monitoring Systems stock

Total Debt to EBITDA Ratio of Non-Invasive Monitoring Systems is -3.72 in 2026.

Total Debt to EBITDA Ratio of Non-Invasive Monitoring Systems changed from -2.82 to -3.72, representing a 31.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Non-Invasive Monitoring Systems since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Non-Invasive Monitoring Systems with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Non-Invasive Monitoring Systems

All Key Metrics — Non-Invasive Monitoring Systems